547 The prevalence of allergic and non-allergic respiratrory symptoms in the U.S. population: Data from the second National Health and Nutrition Examination Survey,1976–1980 (NHANES II)

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

“…In a survey, skin prick testing with eight nonstandardized extracts of inhalant allergens confirmed that perennial rhinitis was often associated with allergy as there was an excess of skin prick test positivity to cat or dog among individuals suffering from perennial rhinitis (275,285).…”

“…With age, rhinitis symptoms tend to become milder (252,275,721) and simultaneously the allergic skin reactivity decreases in the elderly (1039). Some studies found an increased prevalence of allergic rhinitis in young adults (1040)(1041)(1042)(1043)(1044)(1045)(1046).…”

“…• the second National Health and Nutrition Examination Survey (275,285) The prevalence of an IgE sensitization to aeroallergens measured by allergen-specific IgE in serum or skin tests is over 40-50% in the population of Europe, the USA and Australia-New Zealand (68,(856)(857)(858)(859). Most but not all sensitized subjects suffer from allergic rhinitis and/or asthma.…”

Asthma Genetics and Intermediate Phenotypes: A Review From Twin Studies

“…Although asthma occurs throughout the world, large geographical and ethnic differences in asthma prevalence have been reported, varying from 0.5% to 6% (Kerkhof et al, 1994;Platts-Mills & Carter, 1997;Rijcken et al, 1996;Turkeltaub et al, 1991;Woolcock et al, 1987), and countries are classified by their asthma rates into low incidence countries (Africa and Asia), medium incidence countries (USA, Canada, European countries and the United Kingdom) and high incidence countries (New Zealand and Australia) (Burney et al, 1996). Different prevalences have been found in urban and rural areas.…”

Omalizumab Improves Asthma-Related Quality of Life in Children With Allergic Asthma

“…1 Nearly 90% of children with allergic diseases have positive skin tests to a common aeroallergen (eg, house dust mite, Alternaria, cockroach, cat, dog), indicating the presence of raised levels of circulating immunoglobulin E (IgE). [3][4][5][6][7] Omalizumab (Xolair; Genentech, San Francisco, CA) is a recombinant humanized monoclonal anti-IgE antibody that forms complexes with circulating free IgE and prevents it from binding to high-affinity receptors on effector cells, thereby inhibiting allergen-induced activation. 8 -10 It has been reported that subcutaneous treatment with omalizumab reduces the requirement for inhaled corticosteroids while protecting against disease exacerbation in a large placebo-controlled trial in children with moderate-to-severe allergic asthma.…”